Should You Invest in EssilorLuxottica Stock From the Philippines in 2025?

Why trust HelloSafe ?

At HelloSafe, our expert has been tracking the performance of EssilorLuxottica for over three years. Every month, hundreds of thousands of users in the Philippines trust us to analyze market trends and identify the best investment opportunities. Our analyses are provided for informational purposes and do not constitute investment advice. In accordance with our ethical charter, we have never been, and will never be, compensated by EssilorLuxottica.

What is EssilorLuxottica?

How much is EssilorLuxottica stock?

The price of EssilorLuxottica stock is rising this week. As of the latest update, EssilorLuxottica trades at €252.90, with a strong 24-hour increase of €13.50 (+5.64%) and a weekly gain of 6.84%. The company commands a substantial market capitalization of €116.62 billion and sees average trading volumes of 636,777 shares over the past three months. Its P/E ratio stands at 34.45, with a dividend yield of 1.65%, reflecting a blend of growth and regular returns. While beta is not specified, impressive performance and innovation may offer compelling investment potential, but short-term volatility could be expected.

Our full analysis of the EssilorLuxottica stock

After a thorough review of EssilorLuxottica’s recent financial results and analyzing its stock performance over the last three years, we have combined a diverse set of financial indicators, technical signals, market developments, and competitive benchmarks through our proprietary algorithms. This allows us to present a nuanced view of the company’s current positioning and future prospects. So, why might EssilorLuxottica stock once again become a strategic entry point into the global medical technology and eyewear sector in 2025?

Recent performance and market context

EssilorLuxottica stock has performed exceptionally well in 2025, recently closing at €252.90 with a robust one-day increase of €13.50 (+5.64%) and a weekly gain of 6.84%. Over the past year, the stock has appreciated by more than 28%, outpacing many European blue chips and reflecting strong operational execution. The company boasts a substantial market capitalization of €116.62 billion and is listed on Euronext Paris—making it a leading player not only in its sector but also across global stock indices. Recent momentum has been fueled by the company’s Q1 earnings beat, accelerated product launches in smart eyewear, and Meta’s strategic equity investment, which confirms the group’s role as a central innovator in wearable technology. The global macroeconomic environment remains supportive for the sector, driven by rising demand for digital health solutions, demographic shifts, and increasing consumer preference for premium vision care—all highly relevant in the Philippine context due to urbanization and growing health awareness.

Technical analysis

Technically, EssilorLuxottica’s current chart structure remains compelling. The stock is trading near the upper end of its 52-week range (€188.25–€298.00) and displays strong bullish momentum. The RSI of 78.6 reflects overbought conditions, indicating investor enthusiasm, while also flagging possible short-term consolidation. MACD (4.79) provides a solid buy signal, and the convergence of moving averages (20-, 50-, 100-, and 200-day) all reside below the spot price, underlining an entrenched uptrend. Current support is found at €246.80, with an initial resistance level at €256.50, and most technical models echo a “Strong Buy” consensus. Trading volumes have picked up as well, confirming the validity of breakouts, and technical participants are likely to capitalize on short-term retracements for measured entries.

Fundamental analysis

Fundamentally, EssilorLuxottica delivers an impressive growth profile. Q1 2025 revenue climbed 8.1% year-on-year to €6.85 billion, with direct-to-consumer sales up 11%, and all geographies—EMEA, North America, and especially Asia-Pacific—reporting robust gains. The company’s operating margins and profitability remain industry-leading, supported by a diversified brand portfolio (Ray-Ban, Oakley, Oliver Peoples, Varilux, Transitions) and successful vertical integration from manufacturing to retail (over 17,500 stores worldwide). The trailing P/E ratio of 34.45 and price-to-sales ratio of 4.15 reflect a premium valuation, but this is warranted given superior growth trends, innovation leadership in AI-powered smart eyewear, and expanding market share. Dividend yield stands at 1.65%, with consistent payout growth confirmed (2025 dividend €3.95 per share, up from €3.23 in 2024). Notably, the Meta investment further validates the company’s direction and prospects in the technology arena. In the context of a maturing yet highly innovative industry, these fundamentals justify renewed interest.

Volume and liquidity

EssilorLuxottica’s liquidity profile is attractive to both institutional and retail investors. Average daily volume is 636,777 shares (3-month average), ensuring a liquid and efficient trading market with tight bid-offer spreads. The robust free float of 62.83% offers ample room for international and regional portfolio flows, including funds from the Philippines seeking eurozone exposure within a globally recognized industry leader. The scale and depth of liquidity also facilitate technical and fundamental-driven trading strategies, making the stock suitable for a broad spectrum of investor profiles.

Catalysts and positive outlook

• Meta’s acquisition of a ~3% stake (worth €3 billion) marks a transformational partnership, with prospects for expansion to 5% and extensive collaboration on Ray-Ban Meta and Oakley Meta smart glasses. These joint projects are at the forefront of wearable AI and smart health tech.
• Ongoing launches of new products—including Nuance Audio hearing-enhancing eyewear and performance AI glasses for athletes—strengthen the pipeline and diversify growth drivers.
• The completion of GrandVision integration is yielding operational efficiencies, cost reductions, and improved market access, particularly in expanding Asia-Pacific markets.
• The focus on premiumization and geographic expansion, especially in China and Southeast Asia, aligns well with health and lifestyle trends among the Philippine population.
• Strong ESG credentials and sustainability initiatives bolster the investment case, as global and Asian investors prioritize responsible corporate citizenship.
• Analyst consensus remains bullish, with 20 covering analysts averaging a €260.11 target price (+8.65% upside) and multiple “Buy” recommendations.
• Financial targets for 2026 are ambitious yet credible: revenue of €27–28 billion and adjusted operating margins of 19–20% highlight management’s commitment to sustainable growth and regular returns for shareholders.

Investment strategies

• Short-term traders might look to capitalize on temporary technical consolidations and breakout moves, especially as the RSI normalizes from overbought conditions.
• Medium-term investors may focus on accumulating positions on minor pullbacks or ahead of scheduled catalysts like Q2 2025 earnings (July 27, 2025) and upcoming product launches.
• Long-term investors can anchor their view on the company’s status as the global leader in eyewear, persistent brand innovation, geographical and channel diversification, and sustained top- and bottom-line growth targets.
• Ideal positioning may be achieved through staged entries, especially during volatility tied to earnings, major technology partnerships, or sector rotations toward quality growth within global equities.

Patience and focus on the broad strategic picture are rewarded, as the stock’s historical track record and current pipeline reflect robust compounding potential.

Is it the right time to buy EssilorLuxottica?

EssilorLuxottica stands out as a premier European and global franchise with remarkable market positioning, strong financials, and a forward-looking strategy anchored by continual product innovation, digital expansion, and top-tier brand strength. Technicals and fundamentals converge at this juncture, suggesting the stock may be entering a new bullish phase following a period of strong momentum and multiple value-enhancing catalysts. While premium valuation reflects the market’s appreciation for growth and quality, structural attributes and a successful partnership-driven model continue to fuel upside.

For Philippine investors looking to achieve global diversification through participation in the rapidly evolving field of healthtech and premium consumer brands, EssilorLuxottica seems to represent an excellent opportunity. The intersection of next-generation technology, consumer health trends, and proven operational excellence forms a solid base for sustainable capital appreciation and portfolio enhancement in 2025 and beyond.

From smart eyewear innovation to resilient financial growth, EssilorLuxottica is well positioned to lead the sector’s next transformation—making the current market environment highly attractive for those considering new exposure.

How to buy EssilorLuxottica stock in the Philippines?

Buying EssilorLuxottica stock online is simple and secure with a regulated broker, whether you're in the Philippines or abroad. Investors usually choose between two main methods: buying shares directly through spot (cash) transactions for long-term ownership, or using CFDs (contracts for difference) to trade on price movements with leverage. Each method offers unique benefits suited to different profiles and risk preferences. To help you compare the best options, a broker comparison can be found further down the page.

Spot buying

A cash (spot) purchase means you buy EssilorLuxottica shares outright and become a direct shareholder. Brokers typically charge a fixed commission per order—often around ₱250–₱300, or about $5 USD, per trade.

EssilorLuxottica Share Gain Scenario

If the EssilorLuxottica share price is $275 (USD), you can buy around 3 shares with a $1,000 stake, including a brokerage fee of around $5.

Gain scenario: If the share price rises by 10%, your shares are now worth $1,100. Result: +$100 gross gain, i.e. +10% on your investment.

Trading via CFD

CFD trading lets you speculate on EssilorLuxottica share price changes without owning the actual stock. Fees involve a market spread and overnight financing costs if you hold leveraged positions for more than a day.

CFD Gain Scenario with Leverage

You open a CFD position on EssilorLuxottica shares, with 5x leverage. This gives you a market exposure of $5,000.

If the stock rises by 8%, your position gains 8% × 5 = 40%. Result: +$400 gain, on a bet of $1,000 (excluding fees).

Final advice

Always compare brokers’ fees, trading platforms, and account conditions before you invest. Your choice between cash buying or CFD trading should match your investment goals, risk tolerance, and trading style. For details on fees and broker offers, check the comparison table further down the page.

Our 7 tips for buying EssilorLuxottica stock

The latest news about EssilorLuxottica

Meta’s acquisition of a 3% stake in EssilorLuxottica boosts confidence in wearable tech strategy. This investment, completed last week for an estimated €3 billion, enhances EssilorLuxottica’s alliance with Meta around innovative Ray-Ban Meta smart glasses and next-generation AI wearables. The partnership, with a focus on direct-to-consumer channels, positions both companies for continued leadership in the connected eyewear space—an emerging segment with rising potential in Asia-Pacific, including the Philippines.

Strong double-digit growth in Asia-Pacific signals surging regional demand for EssilorLuxottica products. Q1 2025 results confirm that Asia-Pacific, especially the Philippines’ fast-growing consumer base, delivered one of the company’s highest sales growth rates globally. The launch of premium eyewear and accelerated adoption of Ray-Ban Meta smart wearables across key regional markets underscores EssilorLuxottica’s ability to capture local demand for both vision correction and fashion-forward technology.

EssilorLuxottica maintains robust technical momentum with a +5.64% stock gain in the past week. The Euronext Paris-listed stock reached €252.90 with high trading volume and a technical “Strong Buy” rating. Supported by bullish MACD and moving averages, these market signals reflect both investor optimism and confidence in management’s ability to execute its global innovation roadmap.

Global analyst consensus remains “OUTPERFORM” with increased target price for EssilorLuxottica. Twenty analysts currently cover the stock, raising the average target price to €260.11, translating to notable upside from last close. Positive sentiment is driven by above-forecast financial results, dividends, and the successful integration of technology partnerships which hold particular promise for evolving consumer markets in Southeast Asia, including PH.

Direct-to-consumer revenues jump 11% year-on-year, bolstered by strong premium eyewear sales. The company’s Q1 2025 report highlights exceptional performance of retail and e-commerce channels. Growth in premium-segment eyewear and popular branded products—readily available to Filipino consumers via authorized resellers and global platforms—strengthens EssilorLuxottica’s position across the region.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.